#United States #New York #Levi & Korsinsky #Securities Fraud #Regeneron

Shareholders Alert: Regeneron Pharmaceuticals and Levi & Korsinsky

In a significant legal development, Levi & Korsinsky, LLP has reached out to investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regarding a class action lawsuit. This action aims to recover losses for shareholders affected by supposed securities fraud that occurred between November 2, 2023, and October 30, 2024. With a deadline set for March 10, 2025, for potential lead plaintiffs to come forward, shareholders are urged to consider their rights promptly.

Overview of the Case

The complaint alleges that Regeneron engaged in misleading practices surrounding its sales of an important medication, Eylea. Key allegations include:

• - Regeneron allegedly incentivized distributors to not charge customers more when using credit cards to purchase Eylea, which led to inflated sales figures.
• - The payments made by Regeneron to facilitate these transactions may have misrepresented the actual cost of Eylea, thus violating federal regulations.
• - By not reporting these financial practices accurately, Regeneron is said to have overstated its Average Selling Price (ASP) to federal agencies, leading to breaches of the False Claims Act.

As a result of these activities, the lawsuit claims that statements made by Regeneron's management concerning the company's performance were materially deceptive or lacked a valid basis.

Participation Details

Investors who have suffered losses during the specified period should act swiftly. Levi & Korsinsky emphasizes that any shareholder who qualifies as a class member may pursue compensation without incurring upfront fees. Individuals are also welcome to request lead plaintiff status, though participation in the lawsuit does not necessitate this role.

For those interested in learning more about their eligibility or the ongoing legal proceedings, Levi & Korsinsky has provided avenues for contact. You can reach out to attorney Joseph E. Levi via email or phone for further guidance.

Levi & Korsinsky's Track Record

Levi & Korsinsky is a well-established firm with a history of successfully advocating for shareholders in securities litigation. Over the past two decades, the firm has secured substantial settlements for various plaintiffs, reinforcing its reputation in this specialized legal sector. Ranking prominently in ISS Securities Class Action Services’ Top 50 Report demonstrates its credibility and effectiveness in handling such complex cases.

Next Steps for Shareholders

It is imperative for affected shareholders to be proactive. Mark your calendars for March 10, 2025, and consider discussing your circumstances with a legal expert from Levi & Korsinsky. You might not only find the information helpful in assessing your situation but also gain support in potentially recovering any losses incurred during the tumultuous period for Regeneron.

For any inquiries or to gather more insights into the lawsuit, shareholders are encouraged to contact Levi & Korsinsky's offices directly. The firm remains committed to assisting investors navigate their rights amid these challenging circumstances.

Conclusion

The call to action put forth by Levi & Korsinsky prompts shareholders of Regeneron Pharmaceuticals to evaluate their investments and rights seriously. This is a crucial moment for affected investors; timely communication and action could shape the outcomes of the ongoing legal battle. Stay informed and consider your options carefully as the deadline approaches.